ALX2004 starts phase 1, along with the sixth oncology-focused in vivo Car-T.
ApexOnco Front Page
Recent articles
If Pfizer hands back the estrogen receptor degrader, Arvinas will seek a new partner.
First-in-human study initiations include Boundless Bio’s second asset, and an ADC from Tubulis.
The company reckons its tech could solve problems with current ADCs, but the market isn’t giving it much credit yet.
Brutal FDA briefing documents raise questions about the approvability of imetelstat for myelodysplastic syndromes.
The FDA highlights high death rates and questions overall survival for Carvykti and Abecma.
Another disappointment raises fresh doubts about CytomX’s extensively partnered masked therapeutics.
The Echelon-3 study seemed doomed, but it just read out positively for overall survival.